Inactivation of the type I interferon (IFN-I) pathway is required for MDSCs in cancer to acquire immunosuppressive activity while stabilizing Interferon Alpha/Beta Receptor 1(IFNAR1) combined with interferon induction therapy elicits a robust anti-tumor effect [75]. Here, IFNAR1 is linked to neoplasm.